Venture Capital Access Online | Venture Capital News
Summary
GPBs Curate system can dramatically reduce the overall manufacturing cost, therapeutic yield losses, and process time for producing life-saving cell therapies for cancer and other diseases," said Justin Klein, M.D., co-founder and managing partner at Vensana Capital. "As the industry works to implement reliable, efficient and cost-effective systems for the global deployment of these breakthrough medical treatments, GPB has devised an elegant yet powerful solution for cell separation, washing and concentration. "Our company was founded with a commitment to apply the groundbreaking microfluidic technology we have developed to get people better, and the strength of this $25.5 million financing will ensure we achieve that goal." Launched in 2019, Vensana is actively investing in late development and commercial stage companies across the medtech sector, including medical devices, diagnostics, drug delivery, digital health, and tech-enabled services. Amgen Ventures has committed $625M to invest in biotechs focused on human therapeutics and drug discovery as well as MedTech, such as digital health platforms, data analytics, and value-based approaches.